+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt

Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt

Documenta Ophthalmologica. Advances in Ophthalmology 76(3): 285-296

The clinical progression of the cataract may be influenced by drugs which reduce the denaturation of lens proteins. One of the most promising drugs is the bendazac-lysine salt. The drug was used in a double-blind study of a group of patients with initial cortical cataract in order to evaluate the changes in visual acuity and contrast sensitivity by means of a psychophysical and an electrophysiological method. After 6 months of treatment with bendazac the mean values of visual acuity showed a statistically significant increase in respect to baseline values, as well as an improvement of the threshold of contrast for most spatial frequencies. In the eyes treated with placebo there was no statistical difference between the visual acuity at baseline and after the treatment, but an increase of the contrast threshold for many spatial frequencies. The treatment with bendazac, when compared to the administration of placebo, leads to a statistically significant improvement of the contrast threshold and induces a global improvement on the visual conditions.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 041123919

Download citation: RISBibTeXText

PMID: 2103531

DOI: 10.1007/bf00142688

Related references

Contrast sensitivity in patients with cataract submitted to chronic treatment with bendazac lysine eye drops. Annali di Ottalmologia e Clinica Oculistica 114(10): 1001-1020, 1988

Hepatotoxicity due to lysine salt of bendazac. Scandinavian Journal Of Gastroenterology. 31(2): 206-208, 1996

Plasma levels and metabolism of bendazac lysine salt in man. Bollettino Chimico Farmaceutico 125(8): 298-302, 1986

Oral absorption of bendazac lysine salt in man after repeated administrations. Pharmacological Research Communications 15(5): 461-472, 1983

A comparative study of the oral absorption in man of bendazac and its lysine salt. Bollettino Chimico Farmaceutico 121(2): 87-90, 1982

Critical evaluation of bendazac lysine salt in the treatment of cataract. Bollettino di Oculistica 63(11-12): 1271-1282, 1984

Basic data supporting the use of the l-lysine salt of bendazac in cataract. International Journal of Tissue Reactions 5(2): 217-225, 1983

Inhibition of rat lens aldose reductase by bendazac-L-lysine salt. Enzyme 42(4): 235-237, 1989

Can bendazac lysine salt be effective on the blood retinal barrier in diabetics. Annali di Ottalmologia e Clinica Oculistica 112(9): 803-806, 1987

Effects of bendazac L-lysine salt on X-ray-induced cataract in the rabbit lens. Experimental Eye Research 42(2): 167-175, 1986

Treatment of early cortical cataract experience with bendazac lysine salt. Prensa Medica Argentina 72(11): 380-383, 1985

Tissue distribution, urinary, fecal and biliary excretion of 14C bendazac L-lysine salt in rats. Pharmacological Research Communications 17(5): 425-432, 1985

Studies on the activity of Bendalina (bendazac L-lysine salt) as a scavenger of hydroxyl and superoxide radicals. Wiener Klinische Wochenschrift 97(21): 819-822, 1985

Effects of bendazac L-lysine salt on some metabolic enzymes of glutathione in the rabbit lens after X-irradiation. Italian Journal of Biochemistry 36(3): 153-165, 1987

Effect of an anti protein denaturant and immunomodulator bendazac lysine salt on the incidence of diabetes and insulitis in the nonobese diabetic mouse. Acta Therapeutica 17(3): 245-252, 1991